Epidermolysis bullosa acquisita treated with basiliximab, an interleukin-2 receptor antibody.
Haufs
M G
MG
Haneke
E
E
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000077552:Basiliximab; D001707:Biopsy, Needle; D016107:Epidermolysis Bullosa Acquisita / Q000175:diagnosis / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011993:Recombinant Fusion Proteins; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab